Seminars in radiation oncology
July 1, 2026
Hanna S W Conradi, Jamie N Petersson, Julie M Deleemans et al.
1 citation
Many people with cancer (PWC) continue to experience persistent biopsychosocial and existential challenges across the cancer care continuum. Symptoms such as anxiety, depression, cancer-related fatigue and pain, sleep disturbance, fear of cancer recurrence, cognitive impairment, and reduced quality of life remain highly prevalent during and after treatment, underscoring the need for...
Current opinion in oncology
July 1, 2026
Fatima Zohra Moujahid, Olivier Taymans
Psychological and existential distress are common across the cancer trajectory and can impair quality of life, treatment adherence, and family functioning. Although psychosocial and pharmacological interventions provide meaningful support, their overall effects are often modest. This review examines the emerging role of psychedelic-assisted therapy (PAT) as a potential approach to better...
British Journal of Clinical Pharmacology
July 1, 2026
Marije E. Otto, Gabriël E. Jacobs, Joost C Van Mechelen et al.
Oral administration of (S)-ketamine for treatment-resistant depression (TRD), as alternative to the registered intranasal or off-label intravenous administrations, has high potential. However, it is characterized by an extensive first-pass metabolism, resulting in low (S)-ketamine exposure and high levels of active metabolites, including (S)-norketamine and (S)-hydroxynorketamine. The relative...
Molecular Psychiatry
July 1, 2026
Waki Nakajima, Tetsu Arisawa, Susumu Jitsuki et al.
1 citation
Subanesthetic doses of ketamine, a non-competitive N-methyl-D-aspartate receptor (NMDAR) antagonist, produce rapid and robust antidepressant effects in patients with treatment-resistant depression (TRD). However, after a single administration, the therapeutic benefit is short-lived, and strategies to maintain its efficacy remain unclear. This study focused on the glutamate...
Pharmacological Research
July 1, 2026
Yang Zhou, Wanchen Sun, Yuxuan Fu et al.
Perioperative depressive symptoms (PDSs) are common among patients who undergo major surgery and can lead to worse clinical outcomes. Esketamine has been reported to alleviate PDSs in patients undergoing certain types of surgery. However, there is a lack of evidence from large-scale, multisurgery studies to support its therapeutic effects in individuals with preexisting moderate-to-severe PDSs....
bioRxiv
July 1, 2026
Alena Lemeshova, Feysal Abdirahaman, Haney Haidari et al.
preprint
Treatment-resistant depression and anxiety remain major challenges in psychiatry, particularly in female patients, who are disproportionately affected yet remain underrepresented in preclinical ketamine research. The present study investigated short- and long-term anxiolytic effects of acute subanesthetic ketamine administration in female Wistar-Kyoto (WKY) rats, a validated genetic model of...
Fundamental and Clinical Pharmacology
July 1, 2026
Nina Abukahok, Steven Lawrence, Samrachana Adhikari et al.
Ketamine is increasingly prescribed in an off-label manner to treat psychiatric disorders, raising concerns about direct-to-consumer advertising and the proliferation of clinics offering ketamine for at-home use without direct medical supervision. We aimed to identify and characterize clinics advertising ketamine for psychiatric conditions online in the New York metropolitan area (New York, New...
Brain and Behavior
July 1, 2026
Lena K L Oestreich, Nathalie M. Rieser
Psychedelic and substance-assisted therapies are attracting renewed scientific, clinical, and public interest as potential interventions for mental health disorders, particularly treatment-resistant depression, post-traumatic stress disorder, and substance use disorders. However, as the field moves from early efficacy trials toward clinical implementation, major questions remain regarding...
JAMA Psychiatry
July 1, 2026
Sung Ryul Shim, Hye Su Jeong, Tanner J. Bommersbach et al.
1 citation
While intravenous ketamine is not approved by the US Food and Drug Administration, it is increasingly used with off-label indications as a novel treatment for suicidal and depressive symptoms. To systematically review and metasynthesize the efficacy and safety data for intravenous ketamine in treating major depressive episodes (MDEs). PubMed, PsycInfo, Cochrane Library, and Embase were...
Clinical Pharmacology & Therapeutics
July 1, 2026
Tijana Stojanovic, Kent W Nilsson, Robert Fredriksson et al.
Interest in ayahuasca and its main component, N,N-Dimethyltryptamine (DMT), has currently moved from historical and experimental use into modern clinical development. Yet, current evidence is fragmented, and systematic mapping of trial methods and design choices remains limited. We therefore systematically examined registered interventional trials of DMT, ayahuasca, and DMT combined with...